S-RACMO signs definitive deal for Takara Bio's GMP cell processing CDMO business

S-RACMO and Takara Bio said on November 2, 2026 that they have executed a Master Agreement, the definitive agreement for S-RACMO's succession of Takara Bio's GMP-compliant cell processing CDMO business. S-RACMO is a joint venture of Sumitomo Pharma and Sumitomo Chemical with its head office in Suita, Osaka, and Sumitomo Pharma counts regenerative medicine and cell therapy among its mid to long term growth areas. The two companies signed a basic agreement on July 21 and continued discussions from there. Closing of the transaction is targeted for January 1, 2027.

What moves is personnel, assets and contract projects

If you have cell processing under contract here, the first thing that changes is the counterparty to your contract, not the building the work happens in. Under the agreement, S-RACMO and Takara Bio will proceed with the transfer of personnel, assets, contract projects and other related items. As necessary, S-RACMO may lease a portion of Takara Bio's GMP manufacturing facilities and related premises and keep running certain GMP-compliant cell processing services at those facilities for a transitional period.

The lease is bounded on several counts: it runs in one direction, with S-RACMO leasing from Takara Bio; it covers a portion of the facilities, not all of them; it applies as necessary rather than by default; and it is framed as transitional. The two say they will work together so the business moves across without disrupting services to customers.

Immune cell therapy know-how next to iPS cell and commercial manufacturing experience

Through the transaction, S-RACMO says it will further strengthen the manufacturing technologies, know-how and specialized talent that form the foundation of its CDMO business, and address a broader range of customer needs in Japan and overseas, including cellular immunotherapies such as CAR-T cell therapy.

Atsushi Tsuchida, president and CEO of S-RACMO, said the company will carry forward Takara Bio's expertise and personnel in cellular immunotherapies, CAR-T and TCR-T among them, and combine them with S-RACMO's own experience in iPS cells and commercial manufacturing. Tsuyoshi Miyamura, president and CEO of Takara Bio, said that after considering the future of the business the company concluded that having it continue under S-RACMO, which has extensive experience in commercial manufacturing, is the best way to keep delivering value to customers.

Takara Bio narrows its CDMO focus and stays in the chain as a vector supplier

Takara Bio will focus its CDMO business on key modalities including nucleic acids and plasmids, proteins and enzymes, and viral vectors, which it describes as optimizing its business portfolio and improving operational efficiency.

The company is not stepping away from gene-modified cells. It will supply viral vectors for gene transduction as raw materials for the gene-modified cells that S-RACMO manufactures, and the two say they will advance the collaboration on that basis. For such a product, Takara Bio remains upstream as a raw material supplier while the processing sits with S-RACMO.

What to settle before the closing date

Start with the approval. The registered manufacturing site and the category of the manufacturing license for regenerative medical products decide how much filing work follows. If the change touches registered particulars, the choice between a partial change application and a minor change notification stays with the marketing authorization holder. Even with no change to the process itself, a different company running it can prompt a request to explain comparability.

Agreements have to be signed again. Japan's GQP Ordinance obliges the marketing authorization holder to hold a written agreement with its manufacturers (Article 7, applied to regenerative medical products through Article 21). Settle the scope of what gets re-signed, the route for reporting deviations and out-of-specification results, and whether the people who know the adjustments that are not written into the procedures stay with the business.

Then trace the materials. Lot records and supplier control for the vector, the media and the cells collected by apheresis as starting material have to connect across the transfer. If patient and product identifiers are reassigned, the chain of identity and chain of custody records have to be traced again as well. For an autologous product there is no pre-change material left to put side by side with the new one, so the design of what comparability compares against comes before the change, not after it.

Final responsibility for ensuring that outsourced work is kept under control stays with the party doing the outsourcing (ICH Q10 section 2.7, EU GMP Chapter 7, section 7.4).

On the reagent side, Takara Bio's European subsidiary launched a GMP grade of its MSC-derived EV production medium on October 28. What is settled so far is a signed agreement and a target date. What to watch next is the closing on January 1, 2027, and, for anyone with a project at the site, which services run under the transitional lease and for how long.